Clinical trials: Heart Failure With Reduced Ejection Fraction
Heart Failure with Preserved Ejection Fraction
Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is becoming the most common cause of heart failure worldwide, in part, driven by a rising prevalence of obesity.
- Trial name
- NCT06510270
- Testing
- Dapagliflozin 10 mg once daily, Loop diuretics, Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
- Volunteers
- 70 people
- Sponsor
- Aswan University
Heart Failure
Heart Failure Evaluation Study
Heart failure (HF) is a highly prevalent conditions that impose a significant burden to the patients, the hospital and the healthcare system. In Hong Kong, HF was one of the commonest causes of hospitalization and death.
- Trial name
- NCT05583513
- Testing
- MLHFQ (Minnesota Living with Heart Failure Questionnaire), KCCQ (the Kansas City Cardiomyopathy Questionnaire)
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Heart Failure
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.
- Trial name
- VASCEND (NCT03168568)
- Where
- Switzerland
- Volunteers
- 79 people
- Sponsor
- University of Zurich